Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal To Fight Zika Virus Boosts NIH, CDC Efforts, But Offers No FDA Review Dollars

This article was originally published in The Gray Sheet

Executive Summary

A $1.1bn agreement between the House and Senate to fund the emergency Zika virus response gives millions of dollars to the Centers for Disease Control and Prevention, NIH, and HHS's biodefense unit, but leaves FDA with no extra funds to support reviews of Zika products. The deal would take dollars from Ebola funding and HHS Affordable Care Act efforts as an offset, and is opposed by the president, who says he will veto it.

You may also be interested in...



Quest For Political Capital, Legacy Could Push 'Cures' Over The Finish Line

When Congress returns to work after the summer recess, the House and Senate medical innovation packages may gain momentum as legislators seek a “feather in the cap” for reelection campaigns, and House Energy and Commerce Committee Chair Fred Upton and Vice President Joe Biden look to cement legacies, say legislative analysts. Also, a Zika virus funding rider is expected be attached to a continuing resolution.

Medtech In Politics: A Look At Republican And Democratic Party Platforms

The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.

Performance Issues With CDC’s COVID-19 Assay Reagent Slows Rollout Of Test Kits To US States

A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.

Topics

Related Companies

UsernamePublicRestriction

Register

MT038358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel